Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Mucosal melanoma is rare and associated with extremely poor prognosis.No effective treatment
for advanced mucosal melanoma patients.Investigators conducted a randomized phase II study in
patients with previously untreated metastatic mucosal melanoma to characterize the efficacy
and safety of bevacizumab when combined with carboplatin plus paclitaxel.